Thursday, March 1, 2012

Analysis Of Consumer Gold Demand

The year 2011 was yet another positive year for gold. It ended the year 9% higher in terms of U.S. dollars despite of increased price volatility. However, gold demand grew only 0,4% in the year 2011 compared tothe year before. On the other hand, consumer demand for jewellery, bars and coins grew 7,2%. These demand categories accounted for 84,8% of total demand in 2011.
To determine where this demand growth comes from I analyzed consumer demand for gold in selected countries and regions based on data recently released by World Gold Council (WGC).








India and Greater China (China, Hong Kong, Taiwan) accounted for over 50% of total demand for gold jewellery, coins and bars. Europe and VIST (Vietnam, Indonesia, South Korea and Thailand) are the next biggest hoarders of golden items.








Comparison of consumer demand for the precious metal in 2011 to the year before reveals a mixed picture. Consumer demand decreased in India, Middle East and USA while dramatically growing elsewhere in the world.

Changes in consumer demand have a big impact on the price of the yellow metal given the importance of consumer demand in the overall demand picture for physical gold.


Disclosure: Long physical gold via various instruments.

Monday, February 20, 2012

Gold Fever - still on

My first blog post was titled "Gold Fever!" (posted on February 12th, 2010). I wanted to go back to that article to look if anything has changed in two years.

The price of gold is now significantly higher than in early 2010. My feeling is that we might have a gold bubble forming, but we have not yet seen the mania phase of the bubble. Two main facts supporting this are:

1) Inflation adjusted gold price in U.S. dollars is far above the levels where it has traded in the last 110 years. However, it needs to be kept in mind that the gold hasn't traded freely during that time period. Gold ownership in USA was illegal between 1933 and 1975. The gold price in U.S. dollars was fixed until 1971. The first bubble in gold was formed during 1971-1980. This followed the liberation of gold and also was a period of high inflation. At the moment, inflation is low.

2) Gold prices have risen for 11 consecutive years and the record high gold price (over $1900) in September 2011 was not that far away from the peak of the previous bubble. The monthly average for January 1980 was $678 ($1919 in 2011 dollars) and all time high was $850 ($2406 in 2011 dollars).



There are many people looking out for exit. This has already led to volatility (wild price changes) and this likely will continue as greed and fear alternate in the minds of the speculators and investors. The last bubble resulted in much faster appreciation (you may call that "the mania phase") and much higher price in real terms than what we saw in September 2011. Therefore, gold still might have long way to go (upwards). How high it goes and whether it bursts in the same way as before remains to be seen.

It all comes down to supply and demand of gold. The demand side looks strong. World Gold Council recently reported that in 2011 investment demand for gold hit record of 1640,7 tons. India, China and Europe were the main drivers of investment demand, which comprises the purchase of gold bars and coins as well as exchanged-traded funds.

Inflation and especially expectations for future inflation will have a big impact on the price of gold in any given currency. For example, purchasing power of the U.S. Dollar has been declining steadily for the last 110 years, except for a few deflationary periods (most notably after 1929).

[You might want to check my old article written for Seeking Alpha titled "Riding the Second Gold Bubble" which review the last 110 years of gold price history as well as supply and demand]

In fall of 2011 we sold part of our gold position. We remain exposed to both the gold itself and to two of the biggest gold miners out there (Newmont Mining and Barrick Gold). Overall, our exposure to gold price continues to be much bigger than what is typically recommended for diversification purposes (2-5%). My investment thesis into gold remains unchanged from what I wrote in my first blog post: "There are many reasons to own gold or any tangible things right now. In my mind, two of the biggest are fear of inflation and fear of another, a far more serious financial meltdown than experienced so far."

Two years ago all eyes were on Greece and they still are. However, now it seems to be much more widely accepted that the problem isn't just Greece or any of the so called "PIIGS" countries. Most of the Western Europe along with USA and Japan has big problems. Huge piles of debt, chronic budget deficits, chronic trade deficits, unemployment and so forth. Politicians go for the we-have-to-grow-our-way-out-of-this -story as they always do. Secretly, they probably hope central bank bails them out because most of the factories have gone East and the prospects of growth are quite limited in the manufacturing sector at least.

Therefore, like so many times in history, countries will resort to money printing in one form or another. Any other way to cover the liabilities and pay back debt is just too painful. I believe this will take place eventually in Europe also. The only reason we have "PIIGS" crisis is that they can't resort to money printing ("quantitative easing" as they call it in U.S.). They no longer have that option after they joined eurozone. They don't have own central bank that can do the trick and Germans don't let them off the hook via European Central Bank (ECB)- for now. Eventually ECB is the only one that can bail out the banks and the countries in Europe.

This is where the yellow metal comes into play. Even though gold is not used broadly as currency right now, it has been used as such in history and may be used once more. It continues to be the ultimate benchmark for currencies. That is why central banks hold it. In the West, central banks have always kept a significant part of their reserves in gold whereas in the East emerging countries have very little gold. Thus, there may be plenty of central bank purchases in the years to come as emerging countries continue to diversify into gold. According to World Gold Council, central banks continued to be net buyers in 2011 (439,7 tons up from 77 tons the year earlier).

The problem with gold is that it does not yield anything. Central banks don't seem to care because it is the ultimate reserve for them. In fact, when interest rates are low, gold is an attractive alternative to traditional bank savings (cash) for anybody. Jeffrey Currie, the head of Goldman Sachs commodity research, reportedly said in Goldman Sachs Global Strategy Conference in London in January 2012: "We will continue to be long on gold until we can see an absolute turn in the rate cycle, which we don't see happening any time soon." [source: Dow Jones Newswires]

The author was long gold and gold mining companies at the time of writing.

Tuesday, January 17, 2012

Portfolio update

Our portfolio is allocated currently 91% to stocks and 9% to gold.

Geographical allocation of stock portfolio:
  • North America 46%
  • Europe 42%
  • Emerging Markets 12%
Sector allocation of stock portfolio:
  • Information Technology 21%
  • Health Care 19%
  • Communication Service Providers 15%
  • Mining & Exploration 13%
  • Low Emission Power Generation 12%
  • Oil & Gas 11%
  • Other 9%

Thursday, January 5, 2012

Portfolio performance 2009-2011

I track the performance of our portfolio against index investing. I have chosen MSCI All country world (ACWI) index as our benchmark index. Our performance during 2009-2011 has been as follows.



Our portfolio is currently defensive (less risky) and less volatile than the ACWI index. Therefore, it has underperformed in bull market and overperformed in bear market. So far (starting from end of 2008) it has produced exactly same results as investment into passive index would have resulted.

My post from a year ago discusses results from years 2009 and 2010. While updating the calculation to include year 2011 I found a couple of errors in the calculation so results for those years are now somewhat different from the previous update.


Our benchmark index 2007-2011 (based on MSCI All Country World Index) 


I have not calculated our performance during 2007-2008 because we were off the market. During that time and also before that our benchmark index would have been different because the investment objective was different and risk level was much lower.


About the "benchmark investment"

I have chosen to construct my own imaginary benchmark index fund out of MSCI ACWI index instead of choosing one particular index fund that tracks the index. The main reason for this is that I would never invest all our money in any particular fund. I would rather choose several funds managed by several companies that as a whole would track the index close enough. My estimate for average cost level for the benchmark investment is 0.5% per transaction and 0.5% per year.

The index data itself is available via MSCI Barra web site as excel-file at least at the time of writing this post. I use a version of ACWI index which has large and mid cap companies in it. I use it with the following parameters:
- EUR (as in euros)
- Daily (as in daily quotations of the index)
- “Net” (as in “With Net Dividends” that takes into account taxes that you would have to pay before you can reinvest back into the fund. “Gross” option reinvests dividends wholly.)

The benchmark investment is always fully invested into the passive index. Starting balance was invested at end of 2008 to the index. By dividing the money with the value of the index, you get “shares in index”.


About calculating the yearly returns

The yearly return of the index and the "benchmark investment" will be different due to addition of money into the brokerage accounts during the year. The yearly returns are simply calculated as
[balance at end of year N] - [(balance at end of year N-1) + (additions to brokerage accounts during the year N)] / [(balance at end of year N-1) + (additions to brokerage accounts during the year N)]

Saturday, December 3, 2011

Orion & patents

There was a question to my previous article on Orion regarding patent expirations and why I think those have been already discounted in the price of the stock. The reason why I think patent cliff is already fully discounted is the fact that this is widely followed stock in Finland and probably by major stockholders around the world. Information about impending loss of patent protection has been in news for a long time know - especially regarding their Parkinson's disease drugs. Market has a habit of discounting all known information to stock price. However, I wanted to take a deeper look and here is what I found out mainly by reading what Orion has published.

According to Orion's Q3 2011 presentation, Entacapone molecule patent expires in November 2012 in EU. It expires a year later in USA (October 2013). This is the key patent for Stalevo, Comtess and Comtan, which are the best selling drugs of the company related to Parkinson's disease. Combined sales of these drugs was 252,7 million euros in 2010. All proprietary drugs for humans based on a molecule patented by Orion are listed in the following table. As you can see, there are not many of them:

Proprietary drugs for humans based on molecule originally patented by Orion

Stalevo enjoys data protection in EU until October 2013. Thus, it will probably take until 2014 that there will be generic competition for Stalevo in EU (this was an estimate in Orion's CMD 2010 presentation). Comtan has data protection in Japan until 2015. Stalevo has not been yet launched there.
It is in Stage III in R&D pipeline. When approved, it should get 6 year exclusivity (my own interpretation).

According to Wikipedia test data exclusivity is as follows:
  • United States: 5 Years for new pharmaceutical chemical entities, 3 years for new indications for pharmaceutical drugs, and 12 years for biologic products.
  • European Union: 8 Years (+ 2 Years market exclusivity + 1 year for new indication)
  • Japan: 6 Years
  • China: The government promised a protection period of 6 years for pharmaceutical drugs, when applying for membership to the World Trade Organization (WTO).
[More about what test data exclusivity means: See http://en.wikipedia.org/wiki/Test_data_exclusivity]

When generic drugs enter the market

Once it is possible for generic drugs to enter the market, they won't eat all of Orions profits overnight. Based on what I found from internet, it seems to be common that generics may take 50% of the market share in 12 months and 80% in 24 months. However, after that the decrease will be slow. The most loyal customers are left. Rather than slashing prices, the company behind the branded drug which has lost protection might actually increase the price of the drug rather than enter into price war with the generic alternatives. Whatever they do they are sure to lose revenue compared to time before the patent expiration.

In case of Orion, it will probably take until 2014 before the effect from losing protection in EU and US for some of its key drugs start to show in results. Meanwhile, a lot can happen. They may launch some new drugs or introduce existing drugs to new markets (like Stalevo for Japan). Also, existing sales of other product segments (>50% of the company) can grow.

Worst case scenario

In the event that they would fail in these actions and top line (net sales) would shrink gradually about 290 million euros by 2020 they could lose 70% of their bottom line unless they would adjust R&D and sales etc. costs. This is very unlikely scenario. Even if they would lose all that sales and get nothing offsetting that they would most certainly adjust their fixed costs (R&D, sales, general costs) to soften the impact on bottom line unless they were sure that investments to R&D and sales would pay off later.

Even in the worst case scenario I would expect them to be able to provide 6,5 euros worth of dividends from the company from years 2011-2020 discounted to this date with 5% rate. All this naturally assumes that they maintain the high payout ratio of over 90% of net result. And even if this worst case would happen you would still have a profitable company although that profits would be smaller and dividend yield not what it is now (compared to current stock price).


Looking at Orion's research areas

In the field of proprietary products, Orion's key compteneces are focused on selected areas of central nervous system disorders and critical care. In recent years, also urology and prostate cancer have become strong areas of expertise. I think these are cleverly chosen areas of expertise. They address mainly aging population. The pharmaceutical industry in general should get lift from this and the fact that the population in developing economies get increasingly wealthy leading to increased standard of living and better access to health care.

R&D pipeline of the company has so far produced 8 proprietary drugs four of which are for humans and four for animals. It has in-licensed patented products such as Enanton, Vantas and Kentera. The easyhaler product line is based on generic active substances. The company does R&D collaboration in cancer research.

The therapy areas of research are:
  • central nervous system
  • oncology (cancer)
  • critical care
  • inhaled medical products
  • generics
  • animal health

R&D pipeline

Stage III (i.e. last clinical phase for marketing authorisation):
  • Easyhaler combined formulations for asthma and COPD (chronic obstructive pulmonary disease)
  • Stalevo for Japanese market (Parkinson's disease)

Stage II:
  • Androgen receptor antagonist for advanced prostate cancer (partner: Endo Pharmaceuticals)
  • Alpha 2c receptor antagonist for Alzheimer's disease
  • Alpha 2c receptor antagonist for Raynaud's phenomenon

Stage I:
  • More effective levodopa product for Parkinson's disease
  • Dexmedetomidine (non-intravenous) for pain management (partner: Recro Pharma)

Pre-clinical:
  • Projects for prostate cancer, neuropathic pain, Parkinson's disease and Alzheimer's disease

Clinical phases typically last as follows according to Orion:
  • Phase III (last stage): More than 3 years
  • Phase II: 1-3 years
  • Phase I (first stage): 1 year